Reduce Hester Biosciences Ltd For Target Rs.2780 - ICICI Direct
Follow us Now on Telegram ! Get daily 10 - 12 important updates on Business, Finance and Investment. Join our Telegram Channel
Weak poultry performance continues to weigh on numbers
About the stock: Hester is one of India’s leading animal healthcare companies & the second largest poultry vaccine manufacturer in the country. It has a strategic presence in 30+ countries with key markets being India, Nepal and Tanzan
* It operates through four broad verticals: poultry vaccines, poultry health products, animal vaccines and animal health products
* Revenue segment wise: poultry healthcare:73%, animal healthcare: 27%
Q1FY23 Results: Numbers weak as poultry farm economics turned adverse.
* Downgraded from HOLD to REDUCE due to adverse demand environment for poultry vaccines, slower ramp-up in Africa business, delay and uncertainty in execution of tenders along with dwindling margins
Target Price and Valuation: We value Hester at | 2015 (base business at | 1967 i.e. 38x FY24E EPS of | 51.8 + NPV of | 49 for Covaxin DS opportunity)
Key triggers for future price performance:
* Opportunities in animal vaccines such as classical swine fever, lumpy skin disease (only player), sheep pox (only player) in the domestic space and expected launch of the modified Inactivated Coryza Vaccine, along with additional revenue from PPR national tender *
Increased focus on health products & widening of portfolio with differentiated herbal line of products looks promising for growth prospects
* Traction from manufacturing from Tanzania facility, Hester Africa and strengthened distribution network in Africa, along with increase in bulk antigen capacity and fill finish line for animal vaccines
* Foray into pet care with 11 products and new marketing teams in four zones
Alternate Stock Idea: Apart from Hester, in our healthcare coverage we like Indoco.
* Indoco manufactures and markets branded formulations and APIs for the domestic and export markets.
* BUY with target price of | 525
To Read Complete Report & Disclaimer Click Here
https://secure.icicidirect.com/Content/StaticData/Disclaimer.html
Above views are of the author and not of the website kindly read disclaimer
